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OBJECTIVE — To compare the ages and sequence in which antibodies associated with type
1 diabetes and celiac disease appear and overt diseases develop in children with an HLA-
conferred susceptibility to both diseases.
RESEARCH DESIGN AND METHODS — We observed 2,052 children carrying ge-
neticrisksforbothtype1diabetesandceliacdiseasefrombirthuntilthemedianageof5.7years
and analyzed diabetes- and celiac disease–associated antibodies in serum samples collected at 3-
to12-monthintervals.DiabeteswasconﬁrmedbyWorldHealthOrganizationcriteriaandceliac
disease by duodenal biopsies.
RESULTS — Altogether 342 children seroconverted to positivity for at least one diabetes-
associatedautoantibodyand88topositivityforatleastoneceliacdisease–associatedantibodyat
the median ages of 3.0 and 1.5 years, respectively (P  0.001). If only children with biochem-
ically deﬁned diabetes-associated autoantibodies against insulin, GAD, or IA-2A protein (n 
146) and children with tissue transglutaminase autoantibodies were compared (n  86), the
median seroconversion ages were 2.5 and 3.0 years (P  0.011). Fifty-one children progressed
toovertdiabetesat4.5yearsand44childrentoceliacdiseaseat4.3years(P0.257).Ofthe19
childrenwhodevelopedbothdiabetes-andceliacdisease–associatedantibodies,3progressedto
both diabetes and celiac disease.
CONCLUSIONS — ChildrenwithHLA-conferredsusceptibilitytotype1diabetesandceliac
disease develop celiac disease–associated antibodies mostly at a younger age or the same age at
which they develop diabetes-associated autoantibodies. Clinical diabetes and celiac disease are
commonly diagnosed at the same median age.
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T
he incidences of type 1 diabetes and
celiac disease are increasing rapidly
(1). These autoimmune diseases of-
ten occur together, as 4.5% of subjects
with recent-onset type 1 diabetes also
have celiac disease, and the coexistence is
evenmorecommoninsubjectswithlong-
standing type 1 diabetes (2,3). Shared
susceptibility alleles in the HLA region
probably contribute to this coexistence
(4).Althoughappearanceofdiabetes-and
celiacdisease–speciﬁcantibodiesstrongly
indicates commencement of autoimmu-
nity (5), antibodies also predict progres-
sion to the respective clinical diseases.
However, in the case of diabetes, in par-
ticular, the time from autoimmunity to
overt disease may vary from months to
years. Interestingly, clinical type 1 diabe-
tes is usually diagnosed ﬁrst and celiac
disease within the following few years
(6,7). The order is rarely reversed (8).
Althoughcoexistenceoftype1diabe-
tes and celiac disease has been studied
mainly in clinical patients, Williams et al.
(9) showed in a cross-sectional study that
5.4% of nondiabetic ﬁrst-degree relatives
of type 1 diabetic patients who were pos-
itive for diabetes-associated autoanti-
bodies were positive also for tissue
transglutaminase autoantibody (TGA).
However,theﬁndingsoftheDiabetesAu-
toimmunity Study in the Young (DAISY)
indicated that the two types of antibodies
rarely appeared simultaneously (10),
whereastheGermanBabyDiabstudysug-
gested that celiac disease–associated anti-
bodies invariably develop later than
diabetes-associated autoantibodies
(11,12).
Here we report the age and order in
which the diabetes- and celiac disease–
associated antibodies and the two clinical
diseases developed in children who car-
riedgenetictype1diabetesandceliacdis-
ease susceptibility and participated in the
type1DiabetesPredictionandPrevention
(DIPP) study.
RESEARCH DESIGN AND
METHODS— All study children were
participants in the ongoing population-
basedDIPPstudy,whichisasurveyofthe
natural course of preclinical type 1 diabe-
tes in genetically susceptible individuals
born in the cities of Turku, Oulu, and
Tampere in Finland (13). After parental
consent, the newborns carrying HLA-
DQB1genotypesconferringsusceptibility
to type 1 diabetes (*02/*0302; *0302/x
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male infants in Turku with HLA-
DQB1*02/x) (13) were observed from
birth for the appearance of diabetes-
associated antibodies. The at-risk chil-
dren in Turku were examined at 3-month
intervals until 2 years of age and then at
6-month intervals. In Oulu and Tampere,
the children were examined at 3, 6, 12,
18, and 24 months and then at 12-month
intervals. At every examination, a blood
sample was drawn, processed, and stored
as described (13).
For this study, we chose an 11-year
cohort of DIPP study children carrying
HLA alleles DQB1*02/DQB1*0302 or
DQA1*05-DQB1*02 and born between
November 1994 and December 2005.
The HLA alleles were determined from
cord blood spots dried on ﬁlter paper us-
ing a semiautomated technique (14). To
document when diabetes autoimmunity
began, islet cell autoantibody (ICA) was
ﬁrst measured from every blood sample
drawn. If the sample was ICA-positive,
autoantibodies against biochemically
characterized autoantigens (insulin
[IAA],GAD[GADA],andproteintyrosine
phosphatase-related IA-2 protein [IA-
2A]) were also analyzed in all samples
drawn from that child since birth. To
evaluate which proportion of children re-
maining ICA-negative but developing
other diabetes-associated autoantibodies
were missed when ICA alone was mea-
sured, we analyzed the four diabetes-
associated autoantibodies in all samples
drawn from a time-restricted cohort of
1,006 DIPP study children (15), in all
samples drawn from children born to au-
toantibody-positive mothers, and in all
samples drawn from children born on or
after 1 January 2003. All children who
developed diabetes-associated autoanti-
bodies were permanently observed at
3-month intervals (13).
We used IgA-class TGA as the pri-
mary marker of celiac disease autoimmu-
nity. We ﬁrst measured TGA in the
samplesdrawnduringtheyear2000from
all children with HLA-conferred diabetes
and celiac disease susceptibility. The age
of the oldest child in the year 2000
screening was 5.2 years. Later, TGA was
ﬁrst analyzed at the age of 1 year in the
children with genetic celiac disease sus-
ceptibility. Taking into account all sam-
ples analyzed, the ﬁrst assessment of TGA
wasmadefromsamplescollectedatame-
dian age (range) of 1.8 years (0.1–9.1).
The children were retested annually until
the end of March 2007, when the oldest
children were 12.3 years. When a child
became TGA positive, antibodies against
endomysium(EMA),reticulin(ARA),and
gliadin (AGA-IgA and AGA-IgG) were
also analyzed in all of the child’s previous
and forthcoming samples (5). TGA was
also measured in the last available sam-
ples from the six children who withdrew
from the follow-up before the year 2000.
The age at seroconversion to antibody
positivitywasdeﬁnedastheagewhenthe
ﬁrst positive blood sample was drawn, ir-
respective of the slight variation in the
intervalsbetweenthelastautoantibody-
negative and the ﬁrst autoantibody-
positive sample.
The diagnosis of type 1 diabetes was
based on the World Health Organization
criteria (16). Duodenal biopsies were rec-
ommended for all TGA-positive children.
If biopsies showed villous atrophy, celiac
disease was diagnosed and a gluten-free
diet was recommended.
The ethics committees of the partici-
pating university hospitals approved the
study. Written informed consent was ob-
tained from the parents for autoantibody
analysis and intestinal biopsies. The
child’s consent was also requested for
children aged 7 years.
Type 1 diabetes–associated
antibodies and celiac
disease–associated antibodies
ICA was quantiﬁed using a standard indi-
rect immunoﬂuorescence method, and
biochemical autoantibodies (IAA, GADA,
and IA-2A) were quantiﬁed using radio-
binding assays (17). TGA was measured
with a recombinant human TGA kit
(Celikey; Pharmacia Diagnostics, Freiburg,
Germany) (18). EMA and ARA were de-
termined by indirect immunoﬂuores-
cence(19,20).SerumAGA-IgGandAGA-
IgA were analyzed by an enzyme-linked
immunosorbent assay (ELISA) (21).
Serum IgA was analyzed when a
child’s antibodies were measured for the
ﬁrst time. If the concentration was 0.05
g/l,IgGclassTGAandAGAwereanalyzed
by ELISA (21).
Positivity for diabetes-associated
antibodies and celiac
disease–associated antibodies
We measured ICA in all samples, and if
the result was positive, we also analyzed
IAA,GADA,andIA-2Ainallpreviousand
forthcoming samples for that child. We
deﬁned the age at seroconversion to pos-
itivity for diabetes-associated autoanti-
bodies as the age when any of the
autoantibodies was positive for the ﬁrst
timeandpositivityforabiochemicallyde-
ﬁned diabetes-associated autoantibody as
the age when the ﬁrst of at least two con-
secutive samples positive for IAA, GADA,
or IA-2A was drawn.
Because TGA was used for the pri-
mary screening of celiac disease autoim-
munity, all children with celiac disease–
associatedautoantibodieswerepositivein
at least one sample for TGA. The age at
seroconversion to positivity for celiac dis-
ease–associated antibodies (TGA, AGA-
IgA,AGA-IgG,EMA,orARA)wasdeﬁned
as the age when the ﬁrst one of these an-
tibodies was positive, alone or in any
combination. For IgA-deﬁcient children,
AGA-IgGandTGA-IgGweremeasuredto
determine the age at seroconversion.
Statistical analysis
We used Wilcoxon’s test to compare dif-
ferences between the median seroconver-
sion ages and Cox’s regression analysis to
compare the development of diabetes-
associated and celiac disease–associated
antibodies. Tests were considered signiﬁ-
cant if two-sided P  0.05. The statistical
analyses were performed using SAS (ver-
sion 9.2; SAS Institute, Cary, NC).
RESULTS
Children positive for
diabetes-associated or celiac
disease–associated antibodies
We ﬁrst analyzed HLA-conferred type 1
diabetessusceptibilityin100,846consec-
utive newborns (Fig. 1) and formed the
cohort of this study by selecting from the
diabetes-susceptible infants those 2,052
who also were at high genetic risk for ce-
liac disease. The median age of the cohort
children at the end of this study was 5.7
years (range 1.0–12.3 years). Boys made
up65%(n1,332)ofthecohortbecause
of the inclusion criteria of the DIPP study
(13).
At least one sample in 342 children
waspositiveforICA(Fig.1),whereas146
children tested positive for at least one
biochemicaldiabetes-associatedautoanti-
body in at least two consecutive samples.
These children included 19 who were
continuously ICA-negative. Altogether
215 children were positive only for ICA,
and 17 were positive in only one sample.
At least one sample in 86 children was
positive for TGA, and 2 children with IgA
deﬁciency were positive for AGA-IgG.
Consequently, 88 children were regarded
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Seroconversion to positivity for the
ﬁrst-appearing celiac disease–associated
antibody occurred at the median age of
1.5 years (range 0.5–7.5), i.e., at a mark-
edly younger age than the seroconversion
to positivity for the ﬁrst diabetes-
associated autoantibody (3.0 years, range
0.4–11.1;P0.001)(Fig.2).Ifonlyper-
sisting biochemical diabetes-associated
autoantibodies were accepted for analy-
sis, the children seroconverted at a me-
dian age of 2.5 years (0.5–10.1), also
clearly later than the children serocon-
verted to celiac disease–associated anti-
body positivity (P  0.007). Restricting
celiac disease–associated antibodies to
TGA, the children seroconverted at a me-
dian age of 3.0 years (1.0–9.0), i.e., at the
same age as the children seroconverted to
positivity for diabetes-associated autoan-
tibodiesbutlaterthantheyseroconverted
topositivityfortheﬁrstbiochemicallyde-
ﬁned diabetes-associated autoantibody
(P  0.011) (Table 1). If we omit AGA-
IgG and AGA-IgA from the analysis, the
medianageatseroconversiontopositivity
for TGA, EMA, or ARA was 2.5 years.
Of the 86 TGA-positive children, 66
children seroconverted ﬁrst to AGA-IgG
positivity. In 40 of them, the ﬁrst sample
positiveforaceliacdisease–associatedau-
toantibody was for AGA-IgG alone. The
time from seroconversion to AGA-IgG
positivity to positivity for another celiac
disease–associated antibody (TGA, EMA,
ARA, or AGA-IgA) was 0.8 years (range
0.2–6.1).
Interestingly, among the 86 children
who seroconverted to TGA positivity, 39
(45%) reverted spontaneously to negativ-
ity, or the values ﬂuctuated at least twice
from negativity to positivity without di-
etary intervention. Although 23 children
wereTGA-positiveinonlyonesample,all
except one showed positivity in the same
sample for AGA-IgG, AGA-IgA, EMA,
and/or ARA. Antibody transience and
ﬂuctuation were common also among
AGA-IgA (24 of 50 [48%]), AGA-IgG (22
of 78 [28%]), EMA (29 of 85 [34%]), and
ARA (26 of 74 [35%]).
During the follow-up, 51 of the 342
children positive for diabetes-associated
autoantibodies progressed to overt diabe-
tes, and 43 of the 88 children positive for
celiac disease–associated antibodies pro-
gressed to biopsy-proven celiac disease.
One additional child developed skin bio-
psy–conﬁrmed dermatitis herpetiformis
at age 4.3 years. Although celiac dis-
ease–associated antibodies developed,
on average, at a slightly younger age
than the diabetes-associated autoanti-
bodies, overt diabetes and celiac disease
were diagnosed at the ages of 4.5 years
(range 1.4–11.6) and 4.3 years (1.6–9.8),
respectively (P  0.257). Twenty-ﬁve
children lost TGA spontaneously before
endoscopy, the parents of three children
refused the procedure, and four children
were on the endoscopy waiting list at the
end of the follow-up.
Children with both diabetes-
associated antibodies and celiac
disease–associated antibodies
Nineteen(5.6%)childrendevelopedboth
diabetes-associated and celiac disease–
associated antibodies. Eight children se-
roconvertedﬁrsttopositivityfordiabetes-
associated autoantibodies, eight ﬁrst to
positivityforceliacdisease–associatedan-
tibodies, and three to positivity for both
types of antibodies. The median ages of
the 19 children who seroconverted to
positivity for the ﬁrst diabetes-associated
autoantibody and the ﬁrst celiac disease–
associated antibody were 1.6 years (range
0.5–6.5) and 1.5 years (0.8–7.2), respec-
tively. Accordingly, the children who se-
roconverted to positivity for both
diabetes- and celiac disease–associated
antibodiesseroconvertedatayoungerage
than those who were positive only for di-
abetes-associated antibodies (1.6 vs. 3.0
years; P  0.026).
Of the 19 children with both dia-
betes-associated and celiac disease–
associated antibodies, 10 were positive
for the biochemical autoantibodies. Four
of them developed ﬁrst IAA, GADA, or
IA-2A; four developed celiac disease–
associated antibodies; and two developed
bothtypesofantibodiesatthesameage.
Thechildrenseroconvertedtopositivity
for biochemical autoantibodies and ce-
liac disease–associated antibodies at the
median ages of 1.4 years (range 0.5–
8.9) and 1.4 years (0.8–2.6), respec-
tively.The3childrenwhoprogressedto
clinical type 1 diabetes and celiac dis-
ease during the follow-up developed
autoantibodies and overt diseases in
random order (supplemental Fig. 3,
available in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-1217/DC1).
CONCLUSIONS — Our ﬁndings
suggest that celiac disease–associated an-
tibodies often develop earlier than or at
the same age as diabetes-associated auto-
antibodies in children with an HLA-
conferredriskforbothdiseases,assuming
that the children are followed up from
birth at frequent intervals. The children
who developed both diabetes- and celiac
disease–associated antibodies generated
Figure 1—Flow chart of the children in the DIPP study. CD-Abs, at least one sample positive for
TGA(IgAorIgG)and/orAGA-IgA,AGA-IgG,EMA,orARA;ICA,atleastonesamplepositivefor
ICA, or ICA and IAA, GADA, and/or IA-2A; T1D-Abs, two consecutive samples positive for IAA,
GADA, and/or IA-2A. *Two children were negative for type 1 diabetes (T1D)-associated autoan-
tibodiesinthelastfollow-upsampledrawn,butwerepositiveinasampledrawnatthetimeoftype
1 diabetes diagnosis.
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random order within a short time inter-
val. Interestingly, the children with ce-
liac disease–associated antibodies
seroconverted to positivity for diabetes-
associated autoantibodies earlier than
those who did not have celiac disease–
associated antibodies. However, overt
diabetes and celiac disease were ulti-
mately diagnosed at approximately the
same age.
Our results differ clearly from those
reported in the BabyDiab study, in which
diabetes-associated autoantibodies devel-
oped earlier than celiac disease–
associated antibodies (12). However, if
the analysis was based only on IAA,
GADA, or IA-2A and only on TGA, sero-
conversion to TGA positivity occurred in
our DIPP study cohort at 3.0 years and
seroconversion to positivity for the bio-
chemical diabetes-associated autoanti-
bodies at 2.5 years. Meanwhile, in the
BabyDiab study, the respective serocon-
versions were seen at 4.9 and 2.3 years.
Thesedifferencesbetweenthetwostudies
are probably explained mainly by the
more frequent follow-up in the DIPP
study,whichpermittedmoreaccuratede-
termination of the seroconversion time.
Indeed, in the BabyDiab study the sam-
ples are collected from antibody-negative
children at the ages of 9 months and 2, 5,
8, 11, and 14 years. None of our DIPP
studychildrenseroconvertedtoTGApos-
itivity before age 1 year, although gluten-
containing foods were almost without
exception introduced between 4 and 6
months of age. However, 23 of the 86
TGA-positive children seroconverted to
TGA positivity between 1 and 2 years of
age, i.e., during the period when the sam-
ples in the DIPP study were still collected
at 3- to 6-month intervals.
When we measured all diabetes- and
celiac disease–associated antibodies to
determinethemedianagesofcommence-
ment of the two autoimmune diseases in
the DIPP study cohort, biochemical dia-
betes-associated autoantibodies devel-
oped slightly later than celiac disease–
associated antibodies (2.5 vs. 1.5 years).
In the BabyDiab study, celiac disease au-
toimmunity was deﬁned as being positive
for TGA in at least one sample, but the
positivity had to be conﬁrmed using both
an ELISA and a radiobinding assay. In the
DIPPstudy,wealsodeﬁnedceliacdisease
autoimmunity as being positive for TGA
with an ELISA in at least one sample; this
was obviously appropriate, because all
children except one were simultaneously
positive also for AGA-IgA, AGA-IgG,
EMA,and/orARA.IntheBabyDiabstudy,
the prevalence of celiac disease–
associated antibody positivity among the
children positive also for diabetes-
associated autoantibodies was 3 of 107
(2.8%). All 3 of these children ﬁrst devel-
oped diabetes-associated autoantibodies.
In our DIPP study cohort, 10 of 146
(6.8%) of the children were positive for
both types of antibodies, closely resem-
bling British data (5.4%), but markedly
exceeding the values obtained in the
BabyDiab study (9,12). Differences in the
study populations may have inﬂuenced
these results, because in the BabyDiab
study, all children had at least one parent
with type 1 diabetes, whereas in the DIPP
study,thechildrenwereselectedfromthe
general population based on HLA-
conferred genetic risk. Unfortunately,
comparison of our ﬁndings with those
from DAISY, another long-term observa-
tional study, is hampered by the fact that
thecoexistenceofdiabetes-associatedand
celiac disease–associated antibodies has
so far not been thoroughly presented.
Glutenhasbeenproposedtobeatrig-
ger of not only celiac disease but also type
1 diabetes. If that is the case, avoidance of
gluten ingestion might delay progression
to type 1 diabetes (22,23). Our frequent
follow-up of the children with a genetic
susceptibility to celiac disease and dia-
betes indicates that celiac disease–
associated autoimmunity often develops
at a slightly younger age than diabetes-
associated autoimmunity, supporting the
hypothesis that a gluten-free diet might
indeed prevent or delay diabetes autoim-
munity.Interestingly,diabetes-associated
autoantibodies developed at a younger
Figure 2—Cumulative seroconversion to positivity for type 1 diabetes (T1D)- and celiac disease
(CD)-associatedantibodiesintheDIPPstudychildrenwithHLA-conferredgenetictype1diabetes
and celiac disease susceptibility. A: Cumulative seroconversion to positivity for diabetes-
associatedandceliacdisease–associatedantibodies(P0.001).B:Cumulativeseroconversionto
positivity for one or more of the persisting biochemical diabetes-associated autoantibodies and to
positivity for TGA (P  0.011). TGA, at least one sample positive for TGA. For other abbrevia-
tions, see Fig. 1.
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diabetes- and celiac disease–associated
antibodies than in children who were
positive for diabetes-associated autoanti-
bodies only.
Weincludedinthisstudyallchildren
who developed diabetes-associated and
celiac disease–associated antibodies dur-
ing the follow-up using overt clinical type
1 diabetes as the end point of the study
(24). Thus, we have data only until the
diagnosis of diabetes from the children
who progressed to diabetes, and some
children may have developed celiac dis-
ease after the diagnosis of diabetes. How-
ever, the purpose of this study was to
evaluate the early phases of diabetes and
celiac disease autoimmunity, not to chal-
lenge previous studies analyzing the risk
of celiac disease once type 1 diabetes has
developed (2,3,6–8).
Our study has some obvious limita-
tions. One is caused by the use of ICA as
theprimaryautoantibodyfordiabetesau-
toimmunity screening in children born in
1994–2002, although we also analyzed
the three biochemical autoantibodies in
all samples drawn from the ICA-positive
children. In children born between the
beginning of 2003 and the end of the
study, all four diabetes-associated auto-
antibodies were directly analyzed in all
samples collected. Our recent study
showed that 82% of the samples that
were positive for the ﬁrst autoantibody
werepositiveforICA,whereasICAorIAA
accounted for 93% of the positive sam-
ples. The sensitivity of our current pro-
gramwhentestedusingICAasthemarker
of commencement of diabetes-associated
autoimmunity is 86% (24), and 10% of
childrenwithautoantibodiesaremissedif
ICAonlyisanalyzed.Wehavealsoshown
that 95% of all IAA, GADA, and IA-2A
seroconversions occur in young children
in a narrow time window (12 to 8
months) around the time of ICA serocon-
version(17).Ofthe2,052childreninthis
cohort, 19 were positive for biochemical
diabetes-associated autoantibodies while
being continuously ICA negative. Conse-
quently, we probably missed a few chil-
dren who were ICA-negative but had
other diabetes-associated autoantibodies.
Deﬁning diabetes autoimmunity as posi-
tivity for the biochemical autoantibodies
does not eliminate the problems associ-
ated with the use of ICA, but it excludes
from the study population the children
whoarepositiveforICAonly.Inanycase,
deﬁning onset of diabetes-associated au-
toimmunity by seroconversion to persist-
ing positivity for at least one of the
biochemical autoantibodies allows better
comparison of our data with those ob-
tained in the BabyDiab study.
AnotherlimitationinourDIPPcohort
study is that we used AGA-IgG as one of
the celiac disease–associated antibodies.
AGA is highly unspeciﬁc, and 25% of
the TGA-negative children with genetic
celiac disease susceptibility were AGA-
IgG–positive in the DIPP study (data not
shown). However, we think that analyz-
ing AGA-IgG together with other celiac
disease–associated antibodies is justiﬁed,
because seroconversion to AGA-IgG pos-
itivity may identify the time when the ce-
liac disease process really begins in
children who also develop other celiac
disease–associated antibodies. AGA-IgG
mayalsobeimportantwhenceliacdisease
triggers other than gluten are searched
for. We previously also measured anti-
bodies to the deamidated gliadin peptide
in part of the currently studied children
(25); the ﬁndings showed high concor-
dance with the AGA and TGA results.
The follow-up schedules of the chil-
dren at the three study centers in Finland
differedslightly,asthechildrenwereseen
more frequently in Turku than in Oulu
and Tampere (17). Analysis of the data at
the three sites slightly postponed the se-
roconversion ages in Oulu and Tampere
for celiac disease–associated antibodies
but not for diabetes-associated autoanti-
bodies for unknown reasons (data not
shown). However, these changes in the
seroconversionagesareminoranddonot
change the conclusions of our study. On
the other hand, the frequent follow-up is
alsoamajorstrengthofourstudy,permit-
ting rather accurate determination of
events contributing to progression to
overt clinical diabetes and celiac disease;
even the less frequent follow-up schedule
is three times more frequent than the fol-
low-up in the older groups in the Baby-
Diab study.
In summary, this population-based,
prospective follow-up study suggests that
celiac disease–associated antibodies often
develop earlier than or at the same age as
type 1 diabetes–associated autoantibod-
ies in children with a genetic susceptibil-
ity to both diseases.
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